Sera Prognostics Inc
NASDAQ:SERA

Watchlist Manager
Sera Prognostics Inc Logo
Sera Prognostics Inc
NASDAQ:SERA
Watchlist
Price: 3.06 USD 2% Market Closed
Market Cap: 118.1m USD

Sera Prognostics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sera Prognostics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Sera Prognostics Inc
NASDAQ:SERA
Revenue
$77k
CAGR 3-Years
-1%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Sera Prognostics Inc
Glance View

Market Cap
118m USD
Industry
Biotechnology

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

SERA Intrinsic Value
1.14 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Sera Prognostics Inc's Revenue?
Revenue
77k USD

Based on the financial report for Dec 31, 2024, Sera Prognostics Inc's Revenue amounts to 77k USD.

What is Sera Prognostics Inc's Revenue growth rate?
Revenue CAGR 5Y
14%

Over the last year, the Revenue growth was -75%. The average annual Revenue growth rates for Sera Prognostics Inc have been -1% over the past three years , 14% over the past five years .

Back to Top